The corona vaccination program across the country will start from January 16, i.e. after the completion of Kamurta. The government made the announcement on Saturday. Initially, the vaccine will be given to health workers and frontline workers, numbering 30 million. The second phase will be given to people above 50 years of age and the third phase will be given to people below 50 years of age suffering from serious illnesses. About 270 million people will be vaccinated in the second and third phases.
There will be two doses of the vaccine. Which will be given at intervals of 28 days. All will have to take two doses, only then will the vaccine schedule be completed. Two weeks after giving the second dose, the body will develop antibodies that protect against the corona. Antibodies are proteins needed by the body to counteract attacks by viruses, bacteria, fungi and parasites
Modi held a meeting to get information about the preparations
Prime Minister Narendra Modi held a high-level meeting on Saturday to review the situation of Corona in the country. He also reviewed the states ’preparations for vaccination. The meeting was also attended by the Cabinet Secretary, Principal Secretary, Health Secretary and other senior officials.
After which Prime Minister Narendra Modi congratulated the country on social media and wrote, “India is going to take an important step forward in the fight against Kovid-19 on January 16. From this day onwards a vaccination drive will be launched at the national level. All frontline workers, including cleaners, will be given priority. “
2 vaccines have been approved in the country
Two vaccines have been approved for emergency use in the country, including Covishield of Serum Institute of India (SII) and Covacin of Bharat Biotech. The government has issued transportation guidelines for delivering both vaccines to different parts of the country.
What is so special about Covishield?
- The Drug Controller General of India i.e. DCGI has approved two vaccines for emergency use.
- The first vaccine is Covishield, developed jointly by AstraZeneca and Oxford University.
- In India, the Serum Institute of India (SII) produces Covishield.
- Its EFC was 90% when given half dose. A month later he was given a full dose. When both full doses were given, the EFC was 62%.
- The average EFC in both types of doses was 70%. 50 million doses of Covishield are ready.
- The second vaccine is convex in. The results of his Phase-3 trials have not yet come to light. Covexin is made by India Biotech.
- According to the results of its Phase-2 trials, the antibodies made in the body due to covexin will last for 6 to 12 months. 20 million doses of covexin are ready.
Identification of 41 airports for vaccine delivery
Currently, 41 destinations (airports) have been identified across the country where the vaccine will be delivered. Delhi and Karnal have been made mini hubs in North India. In the eastern region, Kolkata and Guwahati will be made mini hubs. Guwahati has been made the nodal point for the entire North-East. Chennai and Hyderabad will be the points fixed for South India.